cant alcohol intake (more than 20 g/day), viral hepatitis [hepatitis B virus (HBV), hepatitis C virus (HCV)], pregnancy, comorbid conditions [chronic obstructive pulmonary disease (COPD), chronic respiratory failure (CRF), cardiac failure], hypothyroidism, consumption of drugs causing fatty change in liver (steroid, oral contraceptive pill, tamoxifen, amiodarone, diltiazem, protease inhibitor). All data were collected from structured questionnaire and analyzed by Statistical Package for the Social Sciences (SPSS) 16 software. Qualitative data was analyzed by chi-square test and quantitative data by Student's t-test. The p value below 0.05 is considered as statistically significant. The NAS score was evaluated based on the published article. The TAAG was calculated after assessing T, A, A, and G in their sera and providing each of the parameters a score (fasting serum triglyceride > ULN, ALT > ULN, AST/ ALT ratio (AAR) ≤ 1 and GGT > ULN). An association of TAAG score of 3 was evaluated with NAS score of each patient.
The study enrolled 43 patients (26 females, 17 males). The body mass index (BMI) and waist circumference was calculated according to Western Pacific Region Office of World Health Organization (WHO) 2000 criteria and International Diabetes Federation 2006 criteria for the South Asians respectively. We grouped the study population (n = 43) into non-NASH fatty liver (NNFL) and nonalcoholic steatohepatitis (NASH). Non-NASH fatty liver was present in 23 patients and NASH was present in 20 patients (Tables 1 and 2) . EJOHG Serum triglyceride (T) level was elevated about ULN in 58.1%; serum ALT (A) level above the ULN in 25.5% NAFLD patients. The AST/ALT (A) ratio was ≤ 1 in 79.0% NAFLD patients. Serum GGT level above the ULN was 25.5% in study population. The TAAG score ≥ 3 had a sensitivity of 40% and specificity of 26.1% not significantly correlates (p = 0.33, chi-square test) to NASH prediction. The receiver operation characteristic (ROC) curve showing TAAG scoring system ≥ 3 had sensitivity 40% and specificity 26.1% to identify NAFLD.
Although this study has shown that the biochemical markers bear limited utility as a noninvasive marker of NAS scoring, ample opportunities remain to alter the entity and definition of TAAG. For example, a level of ALT above 65 IU/L was taken as ULN, but ALT levels of 42 or 30 IU/L may also be considered as ULN. Also, it remains to assess if TAAG score of 2 may have any kind of implication in NAS score or not. However, the utility of TAAG may be checked in bigger sample size.
The lack of correlation of TG levels and inflammatory markers with NAS scale in NAFLD indicates how complex the nature of fibrogenesis is in NAFLD patients. In case of hepatitis due to viral etiology, fibrosis is presumed to be due to inflammation of the liver. However, that may not be vase in case of NAFLD. Although our study failed to show a relation of TAAG with NAS score, it possibly exposes the unique nature of hepatic fibrosis during NAFLD. 
